AGEN - Agenus Inc Stock Price, Fair Value and News

5.53USD+0.22 (+4.14%)Delayed as of 22 Apr 2024, 01:01 pm ET

Market Summary

USD5.53+0.22

Delayedas of 22 Apr 2024, 01:01 pm

4.14%

AGEN Stock Price

View Fullscreen

AGEN RSI Chart

AGEN Valuation

Market Cap

111.2M

Price/Earnings (Trailing)

-0.43

Price/Sales (Trailing)

0.71

EV/EBITDA

-0.46

Price/Free Cashflow

-0.47

AGEN Price/Sales (Trailing)

AGEN Profitability

Operating Margin

98.01%

EBT Margin

-77.21%

Return on Equity

173.5%

Return on Assets

-82.01%

Free Cashflow Yield

-210.53%

AGEN Fundamentals

AGEN Revenue

Revenue (TTM)

156.3M

Rev. Growth (Yr)

195.23%

Rev. Growth (Qtr)

244.66%

AGEN Earnings

Earnings (TTM)

-257.4M

Earnings Growth (Yr)

34.44%

Earnings Growth (Qtr)

24.72%

Breaking Down AGEN Revenue

52 Week Range

5.55

(Low)(High)

Last 7 days

-34.8%

Last 30 days

-51.7%

Last 90 days

-54.2%

Trailing 12 Months

-83.9%

How does AGEN drawdown profile look like?

AGEN Financial Health

Current Ratio

0.44

Debt/Equity

-0.09

Debt/Cashflow

-17.56

AGEN Investor Care

Shares Dilution (1Y)

23.64%

Diluted EPS (TTM)

-13.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	95.0M	99.4M	100.9M	156.3M
2022	309.9M	320.1M	89.9M	98.0M
2021	84.8M	68.5M	306.7M	295.7M
2020	85.3M	96.5M	91.4M	88.2M
2019	115.0M	114.9M	122.0M	150.0M
2018	41.4M	39.8M	38.3M	36.8M
2017	43.6M	41.2M	40.1M	42.9M
2016	26.8M	27.0M	24.6M	22.6M
2015	10.2M	13.5M	18.8M	24.8M
2014	2.7M	4.9M	5.8M	7.0M
2013	3.7M	3.9M	3.7M	3.0M
2012	15.5M	15.3M	15.5M	16.0M
2011	3.1M	3.1M	3.1M	2.8M
2010	0	3.3M	3.4M	3.4M
2009	0	0	0	3.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Agenus Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	armen garo h	acquired	16,348	0.5	32,697	see remarks
Mar 22, 2024	armen garo h	acquired	14,939	0.55	27,163	see remarks
Mar 08, 2024	armen garo h	acquired	14,831	0.67	22,136	see remarks
Feb 23, 2024	armen garo h	acquired	14,834	0.68	21,815	see remarks
Feb 15, 2024	armen garo h	bought	324,050	0.6481	500,000	see remarks
Feb 09, 2024	armen garo h	acquired	14,833	0.75	19,778	see remarks
Jan 26, 2024	armen garo h	acquired	14,833	0.66	22,475	see remarks
Jan 12, 2024	armen garo h	acquired	14,833	0.64	23,177	see remarks
Dec 29, 2023	armen garo h	acquired	19,466	0.83	23,453	see remarks
Dec 15, 2023	armen garo h	acquired	16,182	0.69	23,453	see remarks

Which funds bought or sold AGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	O'ROURKE & COMPANY, Inc	sold off	-100	-8,000	-	-%
Apr 18, 2024	Diversified Trust Co	unchanged	-	-14,440	33,786	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	2.5	-127,216	323,991	0.02%
Apr 16, 2024	Powell Investment Advisors, LLC	added	21.75	-24,350	141,230	0.07%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	added	13.31	-4,116	15,850	-%
Apr 15, 2024	Key Client Fiduciary Advisors, LLC	added	37.99	-17,140	498,202	0.26%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	343	186,974	275,575	0.01%
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	-2,900	6,786	-%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	-99.00	232	-%
Apr 11, 2024	Signature Resources Capital Management, LLC	unchanged	-	-	1.00	-%

Are Funds Buying or Selling AGEN?

Are funds buying AGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGEN

No. of Funds

Unveiling Agenus Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 21, 2024	point72 asset management, l.p.	6.8%	28,268,112	SC 13G
Feb 14, 2024	deep track capital, lp	8.31%	31,697,539	SC 13G/A
Feb 13, 2024	vanguard group inc	7.93%	30,266,890	SC 13G/A
Feb 09, 2024	artal international s.c.a.	4.1%	15,631,235	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	32,236,488	SC 13G/A
Jan 22, 2024	state street corp	2.28%	8,680,267	SC 13G/A
Feb 14, 2023	deep track capital, lp	8.86%	2.7e+07	SC 13G/A
Feb 09, 2023	state street corp	7.42%	22,603,650	SC 13G/A
Feb 09, 2023	vanguard group inc	7.97%	24,281,255	SC 13G/A
Feb 03, 2023	blackrock inc.	8.3%	23,400,423	SC 13G/A

Recent SEC filings of Agenus Inc

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	4	Insider Trading
Apr 05, 2024	8-K	Current Report
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 18, 2024	EFFECT	EFFECT
Mar 15, 2024	S-8	Employee Benefits Plan
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report

Peers (Alternatives to Agenus Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Agenus Inc News

Latest updates

Agenus Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	244.7%	83,801,500	24,314,000	25,296,000	22,902,000	28,385,500	22,772,000	20,926,000	25,941,000	20,261,000	252,954,000	10,730,000	11,719,000	31,265,000	14,832,000	26,945,000	15,128,000	34,502,000	19,940,000	15,715,000	79,891,000	6,451,000
Cost Of Revenue	-14.2%	260,000	303,000	254,000	2,294,000	7,693,000	308,000	2,024,000	543,000	881,000	817,000	667,000	1,105,000	-	911,000	634,000	-	-	-	-	-	-
S&GA Expenses	12.0%	21,177,500	18,909,000	20,415,000	18,237,000	25,035,500	18,105,000	18,914,000	18,953,000	21,971,500	21,385,000	16,650,000	16,352,000	20,030,000	14,380,000	14,195,000	10,613,000	12,318,500	11,512,000	11,405,000	10,805,000	9,724,000
R&D Expenses	29.7%	66,723,000	51,443,000	59,285,000	57,118,000	53,278,500	46,011,000	44,960,000	42,442,000	53,486,000	42,937,000	45,508,000	36,677,000	35,569,500	32,134,000	38,550,000	36,363,000	36,833,500	46,132,000	45,243,000	40,130,000	36,031,000
EBITDA Margin	37.6%	-0.66	-1.07	-1.10	-1.17	-1.15	-1.26	-0.35	-0.36	-0.38	-0.37	-1.64	-1.32	-	-	-	-	-	-	-	-	-
Interest Expenses	-23.1%	636,000	827,000	875,000	830,000	296,000	279,000	289,000	279,000	290,000	285,000	299,000	278,000	284,000	302,000	386,000	204,000	299,000	305,000	308,000	312,000	333,000
EBT Margin	35.5%	-0.77	-1.20	-1.21	-1.27	-1.23	-1.34	-0.38	-0.39	-0.41	-0.39	-1.76	-1.42	-	-	-	-	-	-	-	-	-
Net Income	24.7%	-48,582,000	-64,532,000	-73,430,000	-70,893,000	-74,101,670	-56,715,000	-49,235,000	-50,604,000	-67,606,733	177,277,000	-83,991,000	-54,403,000	-37,660,000	-51,646,000	-48,244,000	-45,271,000	-30,107,000	-45,526,000	-50,686,000	18,454,000	-47,807,000
Net Income Margin	41.3%	-1.65	-2.80	-2.77	-2.64	-2.35	-2.49	0.03	-0.08	-0.10	0.00	-3.32	-2.26	-	-	-	-	-	-	-	-	-
Free Cashflow	40.9%	-40,625,000	-68,683,000	-64,480,000	-60,368,000	-61,684,000	-47,911,000	-61,905,000	-56,935,000	-31,889,000	108,987,000	-57,827,000	-42,940,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.4%	314	335	384	413	414	429	456	441	466	438	192	235	215	204	186	180	155	175	207	246	136
Current Assets	-10.5%	112	126	171	206	213	251	289	290	332	308	93.00	136	114	125	105	103	87.00	107	139	179	75.00
Cash Equivalents	1089.2%	76.00	6.00	11.00	15.00	179	208	228	248	292	257	74.00	119	100	114	79.00	92.00	62.00	93.00	122	158	53.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00
Net PPE	-4.5%	133	140	143	140	133	101	89.00	76.00	60.00	50.00	29.00	27.00	27.00	27.00	29.00	28.00	26.00	25.00	26.00	26.00	25.00
Goodwill	0.2%	25.00	25.00	25.00	26.00	25.00	24.00	24.00	25.00	25.00	25.00	25.00	24.00	25.00	25.00	24.00	23.00	23.00	23.00	23.00	23.00	23.00
Current Liabilities	29.0%	256	198	204	191	189	173	160	163	157	150	169	138	130	147	142	127	122	133	122	106	68.00
Long Term Debt	0.4%	13.00	13.00	13.00	13.00	13.00	-	-	-	13.00	13.00	19.00	19.00	19.00	19.00	19.00	13.00	13.00	-	-	-	13.00
LT Debt, Current	-62.3%	0.00	0.00	1.00	1.00	1.00	13.00	14.00	14.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	14.00	14.00	14.00	0.00
LT Debt, Non Current	0.4%	13.00	13.00	13.00	13.00	13.00	-	-	-	13.00	13.00	19.00	19.00	19.00	19.00	19.00	13.00	13.00	-	-	-	13.00
Shareholder's Equity	-Infinity%	-148	-	-	-	-54.90	-	14.00	28.00	48.00	36.00	-	-	-211	-	-	-	-	-	-	-	-
Retained Earnings	-2.4%	-1,955	-1,909	-1,847	-1,778	-1,709	-1,600	-1,584	-1,538	-1,489	-1,424	-1,602	-1,519	-1,465	-1,400	-1,377	-1,329	-0.02	-1,254	-1,209	-1,158	9.00
Additional Paid-In Capital	0.8%	1,792	1,777	1,751	1,715	1,645	1,615	1,583	1,550	1,520	1,464	1,353	1,329	1,258	1,227	1,156	1,132	1,060	1,055	1,052	1,044	1,005
Accumulated Depreciation	2.0%	62.00	61.00	58.00	56.00	54.00	53.00	52.00	52.00	51.00	49.00	50.00	48.00	47.00	46.00	45.00	44.00	43.00	42.00	40.00	39.00	38.00
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	11.00	-	-	8.00	9.00	7.00	-	7.00	-	-	-
Minority Interest	-13.5%	12.00	14.00	16.00	5.00	6.00	9.00	10.00	12.00	13.00	-6.30	-8.63	-8.29	-7.83	-7.83	-7.34	-6.58	-5.98	-5.18	-4.38	-3.15	-2.08
Float	-	-	-	584	-	-	-	544	-	-	-	1,230	-	-	-	671	-	-	-	407	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	38.1%	-40,402	-65,231	-60,043	-58,526	-47,338	-32,191	-43,453	-52,391	-22,927	131,373	-55,557	-42,744	-35,590	-31,626	-37,375	-34,505	-31,780	-66,087	40,900	76,587	-35,800
Share Based Compensation	-7.1%	5,461	5,881	6,042	5,485	4,259	4,453	4,634	4,991	5,198	4,790	5,588	4,001	2,744	2,723	2,553	2,397	3,048	3,084	1,917	1,843	1,930
Cashflow From Investing	-75.5%	2,824	11,548	517	-11,489	-6,383	-15,636	-4,058	-7,533	-13,299	-27,385	-2,270	-196	-834	-873	-2,090	-644	-1,056	-839	-1,261	-1,501	-601
Cashflow From Financing	-59.4%	7,315	18,038	38,263	56,250	23,773	28,223	27,796	16,038	71,605	78,905	11,792	62,962	24,647	67,283	26,312	65,613	1,268	34.00	-76.00	30,097	43,428
Buy Backs	-96.6%	42.00	1,221	640	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

AGEN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenues	$ 156,314,000	$ 98,024,000	$ 295,665,000
Operating expenses:
Cost of service revenue	(3,111,000)	(10,568,000)	(3,470,000)
Research and development	(234,569,000)	(186,691,000)	(178,608,000)
General and administrative	(78,739,000)	(81,007,000)	(76,359,000)
Contingent purchase price consideration fair value adjustment	556,000	815,000	(11,481,000)
Operating income (loss)	(159,549,000)	(179,427,000)	25,747,000
Other income (expense):
Gain on extinguishment of debt			6,197,000
Loss on modification of debt		(1,937,000)
Non-operating income	37,000	12,571,000	5,051,000
Interest expense, net	(97,925,000)	(61,863,000)	(65,719,000)
Net loss	(257,437,042)	(230,655,670)	(28,723,733)
Dividends on Series A-1 convertible preferred stock	(213,000)	(212,000)	(211,000)
Less: net loss attributable to non-controlling interest	(11,676,000)	(10,582,000)	(4,798,000)
Net loss attributable to Agenus Inc. common stockholders	$ (245,974,000)	$ (220,286,000)	$ (24,137,000)
Per common share data:
Basic net loss attributable to Agenus Inc. common stockholders	$ (0.69)	$ (0.78)	$ (0.11)
Diluted net loss attributable to Agenus Inc. common stockholders	$ (0.69)	$ (0.78)	$ (0.11)
Weighted average number of Agenus Inc. common shares outstanding:
Basic	357,889	281,743	228,919
Diluted	357,889	281,743	228,919
Other comprehensive loss:
Foreign currency translation loss	$ (1,870,000)	$ (577,000)	$ (1,280,000)
Other comprehensive loss	(1,870,000)	(577,000)	(1,280,000)
Comprehensive loss	(247,844,000)	(220,863,000)	(25,417,000)
Research and Development [Member]
Revenue:
Total revenues	38,764,000	16,975,000	244,422,000
Service Revenue [Member]
Revenue:
Total revenues	2,978,000	10,514,000	6,704,000
Royalty Sales Milestone [Member]
Revenue:
Total revenues		25,250,000
Other Revenue [Member]
Revenue:
Total revenues			184,000
Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member]
Revenue:
Total revenues	$ 114,572,000	$ 45,285,000	$ 44,355,000

AGEN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 76,110	$ 178,674
Short-term investments		14,684
Accounts receivable	25,836	2,741
Prepaid expenses	8,098	13,829
Other current assets	2,372	3,194
Total current assets	112,416	213,122
Property, plant and equipment, net of accumulated amortization and depreciation of $61,943 and $54,075 at December 31, 2023 and 2022, respectively	133,421	133,017
Operating lease right-of-use assets	29,606	31,269
Goodwill	24,723	25,467
Acquired intangible assets, net of accumulated amortization of $17,688 and $16,148 at December 31, 2023 and 2022, respectively	4,411	6,228
Other long-term assets	9,336	4,453
Total assets	313,913	413,556
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT
Current portion, long-term debt	146	575
Current portion, liability related to sale of future royalties and milestones	132,502	83,510
Current portion, deferred revenue	18	12,269
Current portion, operating lease liabilities	2,587	1,943
Accounts payable	61,446	40,939
Accrued liabilities	45,283	38,259
Other current liabilities	13,915	11,457
Total current liabilities	255,897	188,952
Long-term debt, net of current portion	12,768	12,584
Liability related to sale of future royalties and milestones, net of current portion	124,556	187,753
Deferred revenue, net of current portion	1,143	1,143
Operating lease liabilities, net of current portion	62,511	63,326
Other long-term liabilities	5,420	14,700
Commitments and contingencies (Note 21)
STOCKHOLDERS' DEFICIT
Common stock, par value $0.01 per share; 800,000,000 shares authorized at December 31, 2023 and 2022; 394,373,240 shares and 305,573,397 shares issued at December 31, 2023 and 2022, respectively	3,944	3,056
Additional paid-in capital	1,792,348	1,644,658
Accumulated other comprehensive (loss) income	(955)	915
Accumulated deficit	(1,955,668)	(1,709,907)
Total stockholders' deficit attributable to Agenus Inc.	(160,331)	(61,278)
Non-controlling interest	11,949	6,376
Total stockholders' deficit	(148,382)	(54,902)
Total liabilities, convertible preferred stock and stockholders' deficit	313,913	413,556
Series A-1 convertible preferred stock [Member]
STOCKHOLDERS' DEFICIT
Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at December 31, 2023 and 2022; liquidation value of $33,886 and $33,673 at December 31, 2023, and 2022, respectively	$ 0	$ 0

About Agenus Inc

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFÃƒÅ¸ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

CEO	Dr. Garo H. Armen Ph.D.
WEBSITE	agenusbio.com
INDUSTRY	Biotechnology
EMPLOYEES	533

Agenus Inc Frequently Asked Questions

What is the ticker symbol for Agenus Inc? What does AGEN stand for in stocks?

AGEN is the stock ticker symbol of Agenus Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agenus Inc (AGEN)?

As of Fri Apr 19 2024, market cap of Agenus Inc is 111.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGEN stock?

You can check AGEN's fair value in chart for subscribers.

What is the fair value of AGEN stock?

You can check AGEN's fair value in chart for subscribers. The fair value of Agenus Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agenus Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agenus Inc a good stock to buy?

The fair value guage provides a quick view whether AGEN is over valued or under valued. Whether Agenus Inc is cheap or expensive depends on the assumptions which impact Agenus Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGEN.

What is Agenus Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, AGEN's PE ratio (Price to Earnings) is -0.43 and Price to Sales (PS) ratio is 0.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agenus Inc's stock?

In the past 10 years, Agenus Inc has provided -0.206 (multiply by 100 for percentage) rate of return.